Aptose Biosciences (NASDAQ:APTO) (TSE:APS) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report released on Tuesday.
According to Zacks, “Aptose Biosciences Inc. is a clinical-stage biotechnology company. The company is advancing therapeutics to treat life-threatening cancers, such as acute myeloid leukemia, high-risk myelodysplastic syndromes and other hematologic malignancies. Its lead program APTO-253 has completed a Phase 1 study in patients with solid tumors. Aptose Biosciences Inc., formerly known as Lorus Therapeutics Inc., is headquartered in Toronto, Canada. “
Other research analysts have also issued research reports about the stock. HC Wainwright set a $9.00 price objective on shares of Aptose Biosciences and gave the company a “buy” rating in a report on Monday, November 26th. B. Riley assumed coverage on Aptose Biosciences in a research note on Friday, November 16th. They set a “buy” rating and a $5.00 target price on the stock. Finally, Roth Capital reissued a “buy” rating on shares of Aptose Biosciences in a research note on Wednesday, December 12th. Two investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $5.63.
Aptose Biosciences (NASDAQ:APTO) (TSE:APS) last issued its earnings results on Tuesday, November 6th. The biotechnology company reported ($0.16) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.19) by $0.03. As a group, equities research analysts expect that Aptose Biosciences will post -0.87 earnings per share for the current fiscal year.
A hedge fund recently bought a new stake in Aptose Biosciences stock. Citadel Advisors LLC purchased a new position in shares of Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 48,239 shares of the biotechnology company’s stock, valued at approximately $125,000. Citadel Advisors LLC owned 0.13% of Aptose Biosciences as of its most recent SEC filing. 3.28% of the stock is owned by hedge funds and other institutional investors.
About Aptose Biosciences
Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.
Featured Article: What factors cause inflation to rise?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aptose Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.